drugset / Trial / NCT05203965
Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant
Phase 0
Recruiting
80 enrolled
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedCrossoverDouble-blindPrevention
Summary
The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.
Timeline
- Start
- 2022-05-17
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mavoglurant | Small molecule | 200 mg | — |
Indications
No indication recorded.